Patients with adenocarcinomas with high CXCL13 infiltration also showed a trend toward improved RFS (median survival of 52 months for the low infiltration group vs. not reached), although the results were not significant (HR: 0.3697 [95% CI: 0.1067, 1.281]) (Figure 2m). This evidence concerns the gene CXCL13 and adenocarcinoma.